Emerging uses for pediatric hematopoietic stem cells

Domen, Jos; Gandy, Kimberly L.; Dalal, Jignesh

doi:10.1038/pr.2011.55

Cited by 14 publications

(4 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past decade, allogeneic MSCs have been widely used as a treatment for hematopoietic diseases. 133,134 Another major advantage is that they can be obtained easily and safely from placental tissue, umbilical cord stroma, and cord blood, whereas NSCs and embryonic stem cells can only be obtained from fetal tissue, thereby raising ethical issues. Transplantation of embryonic stem cells may have undesirable consequences as these cells can transdifferentiate into tumors besides differentiating into the desired tissue type.…”

Section: Stem-cell Based Therapy: Enhancing the Neurogenic Potential mentioning

confidence: 99%

The Endogenous Regenerative Capacity of the Damaged Newborn Brain: Boosting Neurogenesis with Mesenchymal Stem Cell Treatment

Donega

Velthoven

Nijboer

et al. 2013

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Neurogenesis continues throughout adulthood. The neurogenic capacity of the brain increases after injury by, e.g., hypoxiaischemia. However, it is well known that in many cases brain damage does not resolve spontaneously, indicating that the endogenous regenerative capacity of the brain is insufficient. Neonatal encephalopathy leads to high mortality rates and long-term neurologic deficits in babies worldwide. Therefore, there is an urgent need to develop more efficient therapeutic strategies. The latest findings indicate that stem cells represent a novel therapeutic possibility to improve outcome in models of neonatal encephalopathy. Transplanted stem cells secrete factors that stimulate and maintain neurogenesis, thereby increasing cell proliferation, neuronal differentiation, and functional integration. Understanding the molecular and cellular mechanisms underlying neurogenesis after an insult is crucial for developing tools to enhance the neurogenic capacity of the brain. The aim of this review is to discuss the endogenous capacity of the neonatal brain to regenerate after a cerebral ischemic insult. We present an overview of the molecular and cellular mechanisms underlying endogenous regenerative processes during development as well as after a cerebral ischemic insult. Furthermore, we will consider the potential to use stem cell transplantation as a means to boost endogenous neurogenesis and restore brain function.

show abstract

Section: Stem-cell Based Therapy: Enhancing the Neurogenic Potential mentioning

confidence: 99%

The Endogenous Regenerative Capacity of the Damaged Newborn Brain: Boosting Neurogenesis with Mesenchymal Stem Cell Treatment

Donega

Velthoven

Nijboer

et al. 2013

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

show abstract

“…A number of malignant and nonmalignant disorders can be cured or stabilized with allogeneic hematopoietic stem cell transplantation (HSCT) . Outcomes following HSCT have also significantly improved in the modern era of comprehensive supportive care, new conditioning regimens, and better identification and treatment of complications.…”

Section: Introductionmentioning

confidence: 99%

Awareness of cord blood collection and the impact on banking

Bhandari

Lindley

Bhatla

et al. 2017

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

“…According to the Worldwide Network for Blood and Marrow Transplantation (WBMT), one million HSCTs had been performed by the end of 2012 [4]. In addition to conventional uses of HSCT for the treatment of hematologic malignancies, clinical uses have expanded in recent years to include treatment of severe scleroderma [5], diabetes [6], metabolic disorders [7], and even delivery of gene therapy [7, 8]. …”

Section: Introductionmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

Emerging uses for pediatric hematopoietic stem cells

Cited by 14 publications

References 97 publications

The Endogenous Regenerative Capacity of the Damaged Newborn Brain: Boosting Neurogenesis with Mesenchymal Stem Cell Treatment

The Endogenous Regenerative Capacity of the Damaged Newborn Brain: Boosting Neurogenesis with Mesenchymal Stem Cell Treatment

Awareness of cord blood collection and the impact on banking

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Contact Info

Product

Resources

About